Antibiotice S.A.

BVB:ATB Stock Report

Market Cap: RON 1.7b

Antibiotice Balance Sheet Health

Financial Health criteria checks 6/6

Antibiotice has a total shareholder equity of RON879.2M and total debt of RON121.7M, which brings its debt-to-equity ratio to 13.8%. Its total assets and total liabilities are RON1.2B and RON362.0M respectively. Antibiotice's EBIT is RON100.8M making its interest coverage ratio 23.1. It has cash and short-term investments of RON28.9M.

Key information

13.8%

Debt to equity ratio

RON 121.71m

Debt

Interest coverage ratio23.1x
CashRON 28.91m
EquityRON 879.23m
Total liabilitiesRON 361.97m
Total assetsRON 1.24b

Recent financial health updates

Is Antibiotice (BVB:ATB) Using Too Much Debt?

Nov 23
Is Antibiotice (BVB:ATB) Using Too Much Debt?

We Think Antibiotice (BVB:ATB) Can Manage Its Debt With Ease

Jan 13
We Think Antibiotice (BVB:ATB) Can Manage Its Debt With Ease

These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt Safely

Aug 16
These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt Safely

Is Antibiotice (BVB:ATB) A Risky Investment?

Jun 08
Is Antibiotice (BVB:ATB) A Risky Investment?

These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt Extensively

Mar 10
These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt Extensively

Is Antibiotice (BVB:ATB) Using Too Much Debt?

Nov 24
Is Antibiotice (BVB:ATB) Using Too Much Debt?

Recent updates

Is Antibiotice (BVB:ATB) Using Too Much Debt?

Nov 23
Is Antibiotice (BVB:ATB) Using Too Much Debt?

Market Might Still Lack Some Conviction On Antibiotice S.A. (BVB:ATB) Even After 25% Share Price Boost

Jun 07
Market Might Still Lack Some Conviction On Antibiotice S.A. (BVB:ATB) Even After 25% Share Price Boost

Antibiotice S.A. (BVB:ATB) Looks Just Right With A 26% Price Jump

Jan 30
Antibiotice S.A. (BVB:ATB) Looks Just Right With A 26% Price Jump

We Think Antibiotice (BVB:ATB) Can Manage Its Debt With Ease

Jan 13
We Think Antibiotice (BVB:ATB) Can Manage Its Debt With Ease

These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt Safely

Aug 16
These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt Safely

Is Antibiotice (BVB:ATB) A Risky Investment?

Jun 08
Is Antibiotice (BVB:ATB) A Risky Investment?

These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt Extensively

Mar 10
These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt Extensively

Tread With Caution Around Antibiotice S.A.'s (BVB:ATB) 5.8% Dividend Yield

Feb 11
Tread With Caution Around Antibiotice S.A.'s (BVB:ATB) 5.8% Dividend Yield

Calculating The Intrinsic Value Of Antibiotice S.A. (BVB:ATB)

Jan 12
Calculating The Intrinsic Value Of Antibiotice S.A. (BVB:ATB)

Are Antibiotice's (BVB:ATB) Statutory Earnings A Good Guide To Its Underlying Profitability?

Dec 16
Are Antibiotice's (BVB:ATB) Statutory Earnings A Good Guide To Its Underlying Profitability?

Is Antibiotice (BVB:ATB) Using Too Much Debt?

Nov 24
Is Antibiotice (BVB:ATB) Using Too Much Debt?

Financial Position Analysis

Short Term Liabilities: ATB's short term assets (RON462.4M) exceed its short term liabilities (RON205.8M).

Long Term Liabilities: ATB's short term assets (RON462.4M) exceed its long term liabilities (RON156.1M).

Debt to Equity History and Analysis

Debt Level: ATB's net debt to equity ratio (10.6%) is considered satisfactory.

Reducing Debt: ATB's debt to equity ratio has reduced from 30.3% to 13.8% over the past 5 years.

Debt Coverage: ATB's debt is well covered by operating cash flow (115.5%).

Interest Coverage: ATB's interest payments on its debt are well covered by EBIT (23.1x coverage).

Balance Sheet

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 10:34
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Antibiotice S.A. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raluca NegoescuAlpha Finance Romania
Vladimira UrbankovaErste Group Bank AG
Roxana DascaluSSIF IEBA Trust SA